Short peptides from a mouse mutant p53 are recognized by CD4+ and CD8+ T cells, and vaccination with a mutant peptide emulsified in incomplete Freund’s adjuvant leads to tumor inhibition (Noguchi et al., 1994; Theobald et al., 1995). Here, CD8A is linked to neoplasm.